← Evidence library

BIB_337

Ideaya Biosciences + multicentre investigators. Optimum-02 phase 3: darovasertib (PKC inhibitor) + crizotinib in metastatic uveal melanoma — positive topline 2026-04-13; LBA9503 ASCO 2026. Combination superior to anti-PD-1 monotherapy or ipi+nivo in PFS per company-disclosed curves. Not directly relevant for cutaneous-melanoma patient (uveal melanoma is GNAQ/GNA11-driven, biologically distinct, hepatotropic metastatic pattern). Adds to uveal-melanoma toolkit complementing tebentafusp (BIB326). TASK17 forward-watch + TASK18 escalation completeness. [Tasks: 17, 18, 19b] Tier: 1 (ASCO LBA + sp…

Evidence grade

A

Tier

1 (ASCO LBA + sponsor topline)

Cited by tasks

17, 18, 19b

Identifiers

—

Full extracted findings & patient-implication analysis: bibliography/BIB_337/findings.md (research corpus). This page is a short context summary — not individualised medical advice.